Isolectin B4 (IB4)-conjugated streptavidin for the selective knockdown of proteins in IB4-positive (+) nociceptors

Bogen O[1], Araldi D[1], Sucher A[2], Kober K[2], Ohara PT[3], Levine JD[1, 4, *]

[1]Department of Oral & Maxillofacial Surgery, UCSF Pain and Addiction Research Center, University of California, San Francisco, CA, United States; [2]School of Nursing, University of California, San Francisco, CA, United States; [3]Department of Anatomy, University of California, San Francisco, CA, United States; [4]Division of Neuroscience, Department of Medicine, University of California, San Francisco, CA, United States

*Corresponding author: Jon D. Levine, UCSF, 513 Parnassus Avenue, Medical Science Building, Room: S-709, San Francisco, CA94143-0440, USA; E-mail: Jon.Levine@ucsf.edu

Dedicated to the memory of Prof. Dr. Ferdinand Hucho†

Summary: *In vivo* analysis of protein function in nociceptor subpopulations using antisense oligonucleotides and short interfering RNAs is limited by their non-selective cellular uptake. To address the need for selective transfection methods, we covalently linked isolectin B4 (IB4) to streptavidin and analyzed whether it could be used to study protein function in IB4(+)-nociceptors. Rats treated intrathecally with IB4-conjugated streptavidin complexed with biotinylated antisense oligonucleotides for protein kinase C epsilon (PKCε) mRNA were found to have: a) less PKCε in dorsal root ganglia (DRG), b) reduced PKCε expression in IB4(+) but not IB4(–) DRG neurons, and c) fewer transcripts of the PKCε gene in the DRG. This knockdown in PKCε expression in IB4(+) DRG neurons is sufficient to reverse hyperalgesic priming, a rodent model of chronic pain that is dependent on PKCε in IB4(+)-nociceptors. These results establish that IB4-streptavidin can be used to study protein function in a defined subpopulation of nociceptive C-fiber afferents.

Introduction

Nociceptors are a heterogeneous group of sensory neurons specialized for the detection of potentially tissue damaging stimuli (1). Most nociceptors are either thinly myelinated Aδ- or unmyelinated C-fiber neurons (2). Based on differences in neurotrophin dependence and the expression of neuropeptides, C-fiber nociceptors have been further divided into nerve growth factor (NGF)-dependent, peptidergic and glial-derived neurotrophic factor (GDNF)-dependent, non-peptidergic, nociceptors (3). The latter class can, at least in rodents (4), also be characterized by binding to isolectin B4 (IB4) (5) (6), a homotetrameric carbohydrate-binding protein from the African shrub *Griffonia simplicifolia* with high binding specificity for terminal α-D galactopyranose residues (7) (8).

IB4(+)-nociceptors that have been exposed to an inflammatory or neuropathic insult develop long-lasting latent hypersensitivity to inflammatory mediators (9) (10) (11) (12). This phenomenon, hyperalgesic priming, can be demonstrated in behavioral experiments as an enhanced and prolonged hyperalgesic response to the pro-inflammatory cytokine prostaglandin E2 (PGE_2) (13) (14). The associated neuroplasticity in the phenotype of IB4(+) nociceptors depends on protein kinase C epsilon (PKCε) and can be explained by a switch in the intracellular signaling pathway mediating PGE_2 hyperalgesia (15) (16) (17) (18).

Binding of IB4 to α-D galactoside containing glycoconjugates on the plasma membrane of GDNF-dependent, non-peptidergic C-fiber nociceptors induces receptor-mediated endocytosis (19) (20). Various laboratories have used this finding to selectively ablate non-peptidergic C-fibers with IB4-conjugated saporin in order to investigate their functional contribution to pain (21) (22) (23) (24). Based on these studies, we sought to analyze whether this cellular uptake mechanism could be used for the specific transfection of GDNF-dependent, non-peptidergic nociceptors with antisense

oligonucleotides. Here we used IB4-conjugated streptavidin to transfect non-peptidergic C-fibers with a biotinylated antisense oligonucleotide to PKCε mRNA and analyzed its effect on hyperalgesic priming, a well-characterized model for the transition from acute to chronic pain in rodents (13) (14).

Material and Methods

Animals: All experiments were performed on 260–320 g adult male Sprague–Dawley rats (Charles River Laboratories, Hollister, CA, USA). Animals were housed in a controlled environment (21-23ºC, 12-hour day-night cycle, food and water were available *ad libitum*) in the animal care facility at the University of California, San Francisco. Experimental protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of California at San Francisco and in compliance with the National Institutes of Health *Guide for the care and use of laboratory animals*. Every effort was made to minimize the number of animals used in experiments and their suffering.

Randall-Selitto paw-pressure test: Mechanical nociceptive threshold was quantified using an Ugo Basile Analgesymeter® (Stoelting, Chicago, IL, USA), a device that uses a cone-shaped pusher with a rounded tip, to apply a linearly increasing mechanical force to the dorsum of a rat's hind paw, as previously described (25) (26). Rats were lightly restrained in a cylindrical acrylic tube that has lateral ports at one end, to allow easy access to the hind paw for mechanical nociceptive threshold testing. Rats were acclimatized to the testing procedure by placing them in the restrainers and training them with the Analgesymeter for ~2 h per day for 3 consecutive days before measuring baseline mechanical nociceptive threshold. Nociceptive threshold was defined as the force in grams at which a rat withdrew its paw. Baseline mechanical nociceptive threshold was defined as the mean of the three readings taken before test agents were injected.

Drugs and their administration: The selective PKCε agonist, psi ε receptor for activated C kinase (ψεRACK) (27) was purchased from Biomatik (Wilmington, DE, USA), and the proinflammatory

cytokine prostaglandin-E_2 (PGE_2) from Sigma-Aldrich (St. Louis, MO, USA). The selection of drug doses was based on dose-response relationships determined during earlier studies (28) (15). Stock solutions of PGE_2 (1 µg/µl) in 100% ethanol (EtOH) were diluted (1:50) with physiological saline (0.9% NaCl) immediately before intradermal injection. The EtOH concentration of the final PGE_2 solution was 2% (w/v) and the injection volume 5 µl. ψεRACK was dissolved and diluted in physiological saline (c_{final}= 0.4 µg/µl). ψεRACK (1 µg) was administered by hypotonic shock as previously described (12). All drugs were administered via a 30-gauge beveled hypodermic needle connected to a Hamilton micro syringe with polyethylene tubing (PE-10).

Covalent conjugation of streptavidin to IB4: The streptavidin conjugation kit (cat. #: ab 102921) was purchased from Abcam (Waltham, MA, USA) and IB4 (cat. #: L-1104-1) was purchased from Vector Laboratories (Burlingame, CA, USA). All reagents were equilibrated to room temperature (RT) before use. 100 µl of IB4 (c = 2.15 mg/ml), dissolved in sterile phosphate buffered saline (PBS), was activated by the addition of 20 µl of modifier reagent of the streptavidin conjugation kit, and then pipetted onto 100 µg of streptavidin (stochiometric ratio between IB4 and streptavidin = 1:1). This solution was gently mixed and incubated at room temperature for 24 h in the dark. Free excess amine groups on IB4 and streptavidin were inactivated by adding 20 µl of quenching reagent of the streptavidin conjugation kit to the reaction mixture. IB4-streptavidin conjugate was stored at 4ºC until use.

Intrathecal injection of antisense oligonucleotides: The antisense oligodeoxynucleotide (ODN) for PKCε, Biotin-GCO AGC TOG ATO TTG OGC OC (O = C-phosphorthioate) directed against a unique region of the rat mRNA was synthesized by Invitrogen (Waltham, MA, USA). The

corresponding GenBank accession number and ODN position within the mRNA sequence are NM_017171.2 and 420-439, respectively. We have previously proven that this antisense ODN for PKCε can be used to downregulate PKCε expression in rat DRG (9) (26). The corresponding sense ODN sequence for PKCε, Biotin-GGE CGC AFG ATO GAG OTG EC (E = G-phosphorthioate, F = A-phosphorthioate), was used as the control. ODNs were dissolved in ultrapure water to a final concentration of 100 pmol/µl, aliquoted and stored at –20 ºC, until use.

For each injection 2.3 µl IB4-streptavidin (30 pmol of conjugate with 120 pmol of biotin binding sites), 1.2 µl biotinylated ODN (c = 100 pmol/µl) and 16.5 µl PBS were mixed (injection volume = 20 µl), incubated at RT for 5 minutes and transferred into a 3/10 cc insulin syringe with a 29-gauge ultra-fine 1/2-inch fixed hypodermic needle (Walgreens, Deerfield, Il, USA). Rats were briefly anesthetized with 2.5% isoflurane (Phoenix Pharmaceuticals, St. Joseph, MO, USA) to facilitate intrathecal injection, and the hypodermic needle inserted into the subarachnoid space on the midline, between the L4 and L5 vertebrae (29). The intrathecal site of injection was confirmed by the elicitation of a tail flick produced by the insertion of the needle into the intrathecal space and injection of the solution (30). Intrathecal injections were performed on day 1, 4 and 7 and DRG harvested on day 10, to be used for either Western blotting, quantitative real-time PCR (Polymerase Chain Reaction) or immunohistochemical analysis.

Tissue harvesting: Rats treated with antisense or sense ODN were euthanized by exsanguination while under deep isoflurane anesthesia. Then L4 and L5 DRG were surgically removed, snap frozen on dry ice and stored at –80º C until further processing.

Protein extraction: DRG were transferred into homogenization buffer [150 mM NaCl, 50 mM Tris-HCl pH 7.4, 2 mM EDTA, 2% sodium dodecyl sulfate (SDS)] supplemented with complete protease inhibitor cocktail (Roche Diagnostics Corp., Indianapolis, IN, USA) and manually homogenized with a plastic pestle in an Eppendorf tube. Proteins were extracted by incubating the homogenate for 2 hours at RT in an Eppendorf thermomixer at 1400 rpm and separated from insoluble components by centrifugation for 15 minutes at 14,000 rpm in a tabletop centrifuge (Eppendorf, Hamburg, Germany). Protein concentration of the samples was determined using the micro-BCA protein assay kit (Pierce, Rockford, Il, USA) with BSA as a standard.

Western blotting: Changes in PKCε expression were evaluated by Western blotting. Briefly, 20 μg of protein per sample were mixed with 4 x sample buffer (62.5 mM Tris-HCl pH 6.8, 3% SDS, 10% glycerol, 0.025% bromophenol blue), denatured by shaking for 10 min at 500 rpm and 90 ºC in an Eppendorf thermomixer, and electrophoresed on a 4-15% precast polyacrylamide gel (Bio-Rad, Hercules, CA, USA) in 25 mM Tris buffer containing 192 mM glycine and 0.1% SDS. Proteins were transferred onto a nitrocellulose membrane (NC) using the semidry blotting method (transfer time 1 h at 10 V with 47.9 mM Tris, 38.9 mM glycine, 0.038% SDS and 20% methanol). The blotting membrane was saturated by shaking in Tris buffered saline (TBS), pH 7.4, containing 5% BSA and 0.1% Tween 20 (antibody dilution buffer) for 1 h at RT. The NC membrane was cut in half at ~64 kDa and the upper half of the membrane was probed at 4ºC overnight with a 1:500 dilution of a rabbit anti-PKCε antibody (sc-214, Santa Cruz Biotechnology, Dallas, Texas, USA) in antibody dilution buffer, while the lower half was probed at 4 ºC overnight with a 1:1000 dilution of a rabbit anti-β actin antibody (ab8227, Abcam, Waltham, MA, USA), in antibody dilution buffer. Blots were rinsed with TBS containing 0.1% Tween 20 (3 times for 15 min under

shaking at RT) and probed with an anti-rabbit HRP conjugated antibody (NA934V, GE healthcare, Piscataway, NJ, USA) for 2 h at RT. Blots were rinsed with TBS containing 0.1% Tween 20 (3 times for 15 min under shaking at RT) and PKCε and β-actin immunoreactivities were visualized with the enhanced chemiluminescence detection kit (Pierce) and analyzed by computer-assisted densitometry (31).

Immunohistochemistry: Rats received 3 intrathecal injections of either IB4-streptavidin complexed with biotinylated antisense or sense oligonucleotides against PKCε mRNA on day 1, 4 and 7. On day 10 rats were deeply anesthetized with isoflurane and perfused through the left ventricle with 100 ml cold PBS containing 10 U heparin/ml PBS followed by 300 ml methanol-buffered 10% formalin (Thermo Fisher Scientific, Waltham, MA, USA). L4 and L5 DRG were dissected out and transferred to PBS with 30% sucrose and stored overnight at 4°C. The DRGs were then embedded in Tissue Tek (OCT compound, Electron Microscopy Sciences, Hatfield, PA, USA), sectioned in a Leica cryostat at 10 μm and mounted on gelatinized microscope slides (Southern Biotech, Birmingham, AL, USA).

Tissue Tek was removed by rinsing the DRG tissue sections twice with Tris-buffered saline (TBS) containing 0.1% Triton X-100 (TBST). Tissue sections were incubated for 1 hour at room temperature (RT) in TBST, with 10% normal goat serum (Jackson Immunoresearch, West Grove, PA, USA) (antibody dilution buffer). Sections were incubated overnight at 4°C with a 1:500 dilution of a Rabbit (Rb) anti-PKCε antibody (sc-214, Santa Cruz Biotechnology) in antibody dilution buffer, washed three times for 10 minutes each at RT with TBST and probed for 2h at RT with a 1:500 dilution of an Alexa Fluor conjugated Goat anti-Rb antibody (Invitrogen cat. #: A11012) and a 1:1000 dilution of IB4-FITC (Invitrogen, cat. #: I21411) in antibody dilution buffer

supplemented with 0.1mM $CaCl_2$, 0.1mM $MnCl_2$, 0.1mM $MgCl_2$ for 2h at RT (6). Sections were washed three times for 10 minutes at RT with TBST supplemented with 0.1mM $CaCl_2$, 0.1mM $MnCl_2$, 0.1mM $MgCl_2$ and mounted with DAPI containing mounting media (Invitrogen, cat. #: P36935).

RNA extraction and quantitative real-time PCR: Total RNA from L4 and L5 DRG was extracted using Trizol (Invitrogen) and the "PureLink™ RNA Mini Kit" (Invitrogen) according to the manufacturer's instruction. The RNA concentration in each sample was determined using a spectrophotometer (Shimadzu, Santa Clara, CA, USA). RNA was transcribed into cDNA using the "iScript™ Advanced cDNA Synthesis Kit for RT-qPCR" (Bio-Rad, Hercules, CA, USA). The real-time PCR was performed with the "SsoAdvanced™ Universal SYBR Green Supermix" (Bio-Rad) and specific primers for PKCε (Bio-Rad, assay ID: qRnoCID0008431) on the CFX 96™ real-time PCR detection system (Bio-Rad). The PCR program was run under the following conditions: 2 min. at 95 ºC, followed by 40 cycles of 15 s at 95 ºC, and 30 s at 60 ºC. Each sample was run in triplicate. Change in gene expression was determined by the $2^{-\Delta\Delta CT}$ method and expressed as relative change compared to control level (32). Glycerinaldehyde-3-phosphate dehydrogenase (GAPDH) RNA was used as reference gene (Bio-Rad, assay ID: qRnoCID0057018).

Statistical analysis: a) Western blot and quantitative real-time PCR: Statistical comparisons were made with GraphPad Prism 10 statistical software (GraphPad Software In., La Jolla, CA, USA). Comparison between treatments were performed using Student's t-test and a p-value less than 0.05 was considered statistically significant. b) Immunohistochemistry: Statistical comparisons were made with GraphPad Prism 10 statistical software. Comparisons between treatments were

performed using contingency testing and Fisher's exact test. A p-value of less than 0.05 was considered statistically significant. c) Behavior: Statistical comparisons were made with GraphPad Prism 10 statistical software. Comparisons between treatments were performed using two-way repeated measures ANOVA with *Post hoc* analysis. A p-value of less than 0.05 was considered statistically significant.

Results

Transfection with IB4-streptavidin: To evaluate whether IB4-streptavidin can be used as a transfection reagent, rats were treated with a complex of IB4-streptavidin and biotinylated antisense ODN (or for the control biotinylated sense ODN) directed against PKCε mRNA. Two groups of 3 rats each received three intrathecal injections on days 1, 4 and 7 before their L4 and L5 DRG were harvested on day 10. Western blot analysis of protein extracts from DRG from the group that had been subjected to the antisense ODN treatment showed a significant decrease (~40%) in the PKCε expression (9.5 +/-1.2 a.u., [N=3]) compared to the group that was treated with the sense ODN sequence (15.9 +/- 1.3 a.u., [N=3], Student's t-test, P = 0.01, **Fig. 1A, B**) indicating successful knockdown of PKCε.

Immunohistochemistry: To analyze whether the downregulation of PKCε expression is restricted to IB4-positive DRG neurons, an immunohistochemical analysis was performed. Two groups of 3 rats each received three intrathecal injections of either biotinylated PKCε sense oligonucleotides bound to IB4-streptavidin or biotinylated PKCε antisense oligonucleotides bound to IB4-streptavidin on days 1, 4, and 7. Three days later, rats were transcardially perfused with 4% PFA, their L4 and L5 DRG excised and analyzed for PKCε immunoreactivity (**Fig. 2**). A contingency test was performed to compare the proportion of IB4(+)/PKCε(+) neurons between DRGs from rats treated with the IB4-streptavidin biotinylated-PKCε sense ODN complex and rats treated with the IB4-streptavidin biotinylated PKCε antisense ODN complex (IB4(+)/PKCε (+) in PKCε-sense ODN-treated rats [31%, 191/600 neurons, 95% CI = (28-35)%], in PKCε antisense ODN-treated rats [19%, 117/600 neurons, 95% CI = (16-22)%]). Fisher's exact test shows a significant difference between IB4(+)/PKCε(+) neurons in DRG of rats treated with IB4-streptavidin biotinylated PKCε sense ODN and those treated with IB4-streptavidin biotinylated PKCε antisense

ODN [P < 0.0001, N = 600/group (3 rats per group with 200 neurons/DRG per rat; 95% CI were calculated using the Wilson/Brown method)]. A second contingency test was performed to compare the proportion of IB4(-)/PKCε(+) neurons between DRGs from rats treated with the biotinylated PKCε sense ODN IB4-streptavidin complex and rats that were treated with the biotinylated PKCε antisense ODN IB4-streptavidin complex (IB4(-)/PKCε (+) in PKCε sense ODN-treated rats [10%, 65/600 neurons, 95% CI = (8-13)%], in rats treated with PKCε antisense ODN [11%, 70/600 neurons, 95% CI = (9-14)%]). Fisher's exact test shows no significant difference between IB4(-)/PKCε(+) neurons in DRG of rats treated with IB4-streptavidin bound to biotinylated PKCε sense ODN and those treated with IB4-streptavidin bound to biotinylated PKCε antisense ODN [P=0.7, N=600/group (3 rats per group with 200 neurons/DRG per rat; 95% CI were calculated using the Wilson/Brown method). These results demonstrate that the knockdown in PKCε expression is limited to IB4-positive (+) neurons, most of which are known to be non-peptidergic C-fiber nociceptors (33) (34).

Quantitative real-time PCR: To determine whether the decrease in PKCε protein levels in rat DRG is due to antisense ODN-stimulated degradation of transcripts of the PKCε gene or to a reduction in the frequency with which the PKCε mRNAs are translated into the corresponding amino acid sequence we performed a real-time PCR. Rats received three intrathecal injections with either IB4-streptavidin complexed with biotinylated antisense oligonucleotides to PKCε, or IB4-streptavidin complexed with biotinylated sense oligonucleotides to PKCε, on days 1, 4 and 7 before their L4 and L5 DRG were harvested on day 10. Quantitative real-time PCR analysis of RNA extracts from DRG from rats subjected to the antisense treatment showed a significant decrease in the number of PKCε transcripts (24% +/- 2.3%, [N=6], P<0.0001, **Fig. 3**) compared to the group of rats treated with the sense sequence, suggesting that the reduction in cellular

PKCε protein levels is caused by a reduction in the number of transcripts of the PKCε gene in rat DRGs.

Reversal of hyperalgesic priming in IB4(+)-nociceptors: Finally, to assess the potential therapeutic utility of our transfection method, we tested the efficacy of the knockdown on hyperalgesic priming, a well-characterized preclinical model of chronic pain (13) known to be dependent on PKCε activity in IB4(+)-nociceptors (11) (10). Rats were first primed with the selective PKCε activator ψεRACK (15), then treated with the complex of IB4-streptavidin and biotinylated PKCε antisense ODN (or biotinylated PKCε sense ODN for the control), and finally tested for the presence of hyperalgesic priming. Rats treated with the IB4-streptavidin biotinylated PKCε sense ODN complex demonstrate prolonged PGE_2 hyperalgesia, a behavioral phenotype that characterizes the presence of hyperalgesic priming (**Fig. 4**) (9) (13). Rats treated with the IB4-streptavidin biotinylated PKCε antisense ODN complex only show the short lasting PGE_2 hyperalgesia, a behavioral phenotype that characterizes the wild-type nociceptor (9) (13). These results demonstrate that the knockdown of PKCε in IB4(+)-DRG neurons can reverse the neuroplastic changes associated with the primed IB4(+)-nociceptor.

Discussion

Opioids are the most effective analgesics for moderate to severe (acute, perioperative, posttraumatic and chronic) pain (35). However, their many undesirable side effects such as analgesic tolerance and physical dependence, opioid-induced hyperalgesia and respiratory depression mandate the development of novel analgesics (36). Therapeutic oligonucleotides are a possible solution (37) (38) (39) (40). Antisense oligonucleotides, or small interfering RNAs, are potent and highly specific (41) (42) (43), safe (41) (42) (43), their mode of action is understood (44) (45) (46) (47), and their *in vivo* stability has been significantly increased in recent years through chemical modifications (48) (45) (41) (42) (43). In addition, their use has already contributed to a better understanding of many pain syndromes (49) (50) (18) (51) (52) (53) (54).

One of the problems still to be solved is how to limit the uptake of the oligonucleotides to specific cell types (55) (44) (46). The most promising method to date involves the conjugation of oligonucleotides to ligands known to bind to cell surface molecules that are exclusively expressed by the target cells and whose binding is known to trigger the cellular uptake of the ligand-conjugated oligonucleotide via receptor-mediated endocytosis (56) (57) (58) (59) (60) (61). Here we have used this approach to transfect a subpopulation of C-fiber nociceptors implicated in specific pain syndromes (e.g., oxaliplatin-induced painful peripheral neuropathy (62) and spinal nerve ligation (63)) with antisense oligonucleotides for PKCε mRNA. Our Western blot data show that a molecular conjugate of IB4-streptavidin complexed with biotinylated PKCε antisense oligonucleotides can be used to attenuate levels of PKCε in the rat dorsal root ganglia (**Fig. 1**). This result is consistent with the findings that IB4 binds to glycosylated cell surface molecules at a large number of small diameter sensory neurons (64) (65) (66), streptavidin is a biotin binding molecule (67) (68), and the antisense sequence we used is known to effectively downregulate

PKCε expression in rat DRG (9) (26). Our immunohistological data show that the downregulation of PKCε is restricted to IB4-binding neurons (**Fig. 2**), most of which are known to be non-peptidergic C-fiber nociceptors (33) (34). This result is consistent with findings that IB4 binding to α-D-galactosides induces cellular uptake of the "ligand-receptor complex" through receptor-mediated endocytosis (19) (20). Our real-time PCR results show that the number of transcripts of the PKCε gene in RNA samples from DRG from rats treated with antisense oligonucleotides is lower than in RNA samples from DRG from rats treated with the sense oligonucleotides (**Fig. 3**). This suggests that the attenuation of PKCε expression in rats treated with antisense oligonucleotides is due to an RNase H-catalyzed degradation of PKCε mRNA (69) (70). Finally, our behavioral data show that the knockdown of the PKCε expression in IB4-binding neurons can reverse hyperalgesic priming (**Fig. 4**), a chronic pain phenotype known to be mediated by PKCε activity in non-peptidergic C-fiber nociceptors (9) (10) (12). This demonstrates that ligand-conjugated streptavidin can be used to selectively transfect target cells with biotinylated antisense oligonucleotides, and a similar approach using a lectin- or antibody-conjugated streptavidin could also be used for the regulation of proteins in other subpopulations of nociceptors.

Here, we used streptavidin instead of avidin to conjugate with IB4. The rationale for this is, that others have previously used streptavidin-conjugated ligands (56) and antibodies (71) to successfully transfect cells with biotinylated oligonucleotides, and the binding of biotin to streptavidin is pH dependent (67), while the binding of biotin to avidin is itself surprisingly stable under acidic and alkaline conditions (67) (68). One of the major challenges in developing oligonucleotide-based therapies is solving the problem of endosomal escape (48) (72) (73). All oligonucleotides, whether unconjugated, bound to plasma proteins, or as part of a ligand-conjugated complex, are taken up by cells through endocytosis and thus enter membrane-bound

vesicles from which they must escape to fulfill their function. The mechanisms by which oligonucleotides escape from endosomes are still not fully understood (72) (74). However, it is known that the internal milieu of endosomes acidifies over time, which, for example, contributes to the breakdown of ligand-receptor complexes into their components. Given that the affinity of streptavidin for biotin decreases dramatically with decreasing pH (67), we chose to bind IB4 to streptavidin.

Ligand-conjugated oligonucleotides offer several significant advantages over unconjugated oligonucleotides. They have a much higher selectivity and are taken up by cells much more effectively (55) (44) (46). Both factors not only reduce the risk of unwanted side effects, but also allow a significant reduction in the doses needed for a successful knockdown. For example, in this study we used only intrathecal injections of 0.78 µg antisense ODN/dose, while our laboratory typically uses intrathecal injections of between 40 and 120 µg antisense ODN/dose for knockdowns with comparable potency (75) (76). However, a fundamental problem in using ligand-conjugated oligonucleotides is the identification of cell surface molecules that are specific to the target cells since most cell surface molecules are not expressed by only one cell type. This also explains why the development of ligand-conjugated oligonucleotides is so challenging and so far, only a few drugs based on ligand-conjugated oligonucleotides have been approved by the FDA (42) (77) (78).

In summary, we report the successful use of streptavidin-conjugated IB4 to selectively transfect a subset of small-diameter nociceptors, the IB4-binding C-fibers, with biotinylated antisense oligonucleotides for PKCε. Our results provide proof of concept for the regulation of target molecules in other populations of DRG neurons.

Figures:



Figure 1: Effect of intrathecal PKCε antisense oligonucleotides on PKCε expression in rat lumbar dorsal root ganglia. (A) Western blot image of protein extracts from L4/L5 dorsal root ganglia of rats treated with either biotinylated PKCε sense (SE) or antisense (AS) oligonucleotides (bound to IB4 streptavidin). The calculated molecular weight of PKCε is ~83.5 kDa (according to UniProt database entry P09216). β-Actin was used as a loading control. Its calculated molecular weight is ~42 kDa (according to UniProt database entry P60711). (B) Column bar graph showing normalized PKCε immunoreactivity in both groups. Data are presented as mean +/- SEM with N=3 in each group ($P<0.05$).



Figure 2: Knockdown of PKCε in IB4(+) C-fiber afferents. Representative images from L4/L5 DRG from rats treated with either IB4-streptavidin biotinylated PKCε sense ODN (upper image panels) or IB4-streptavidin biotinylated PKCε antisense ODN (lower image panels). Color coding: Red = PKCε immunoreactivity, Blue = DAPI, Green = IB4 immunoreactivity, Yellow = PKCε/IB4 colocalization. Note that up to 40% of all DRG neurons in the rat are IB4 positive (+) and the vast majority are small diameter C-fiber DRG neurons. PKCε immunoreactivity can be observed in small-, medium-, and large-diameter DRG neurons. Interestingly, the vast majority of PKCε expressing DRG (~90%) are IB4 positive (+). Scale bar = 50 µm.



Figure 3: Effect of intrathecal PKCε antisense oligonucleotides on PKCε transcripts in rat L4 and L5 DRG. The histogram depicts the level of PKCε expression in rats treated with either a complex of IB4streptavidin/biotinylated PKCε sense ODN (left) or IB4 streptavidin/biotinylated antisense ODN (right). Gene expression was determined with SYBR green RT-PCR and values (mean +/- SEM) represent expression relative to GAPDH. Rats treated with IB4 streptavidin/biotinylated PKCε antisense ODN show a significant decrease in their PKCε mRNA levels compared to those treated with a mixture of IB4 streptavidin/biotinylated PKCε sense ODN (Student's t-test, P=0.0001, N=6 for each group).



Figure 4: Reversal of hyperalgesic priming: Rats were primed by the intradermal administration of ψεRACK. Starting three days after the injection of ψεRACK, rats received intrathecal injections on day 1, 4, and 7 of IB4-streptavidin complexed with either biotinylated sense or antisense ODN for PKCε mRNA. Three days after the last injection PGE_2 was administered into the same site as ψεRACK before. To test for hyperalgesic priming nociceptive paw withdrawal thresholds were measured prior to and 30 min and 4 h post intradermal administration of PGE_2. PGE_2-induced hyperalgesia remained elevated at 4h in sense-treated rats, indicating the presence of priming. However, hyperalgesia was not present at the 4th h in antisense-treated rats, showing its ability to

reverse priming. A two-way repeated measures ANOVA for the baseline readings showed no significant effect of treatment ($F_{1,10} = 0$, $P > 0.999$), time ($F_{2,20} = 1.25$, $P = 0.308$) and treatment by time interaction ($F_{2,20} = 1.67$, $P = 0.225$). These results show that the two ODN groups did not differ significantly until the PGE_2 injection. A second two-way repeated measures ANOVA that included the two post-PGE_2 injection time points showed significant effects for treatment ($F_{1,10} = 159$, $P < 0.0001$), time ($F_{1,10} = 426.2$, $P < 0.0001$) and treatment by time interaction ($F_{1,10} = 277.9$, $P < 0.0001$). *Post hoc* analysis revealed significant differences between sense and antisense treated rats only 4 h post PGE_2 administration ($t_{20} = 19.74$, $P < 0.0001$).

References:

1. Dubin, A. E. and Patapoutian, A. (2010) Nociceptors: the sensors of the pain pathway. *J Clin Invest* **120**, 3760-3772
2. Basbaum AI, J. T. M. (2014) in *Principles Of Neural Science* (Kandel ER, S. J. H., Jessell TM, Siegelbaum SA, Hudspeth AJ, Mack S, ed.) pp. 530-555, McGraw Hill,
3. Snider, W. D. and McMahon, S. B. (1998) Tackling pain at the source: new ideas about nociceptors. *Neuron* **20**, 629-632
4. Galili, U., Shohet, S. B., Kobrin, E., Stults, C. L. and Macher, B. A. (1988) Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. *J Biol Chem* **263**, 17755-17762
5. Gerke, M. B. and Plenderleith, M. B. (2001) Binding sites for the plant lectin Bandeiraea simplicifolia I-isolectin B(4) are expressed by nociceptive primary sensory neurones. *Brain Res* **911**, 101-104
6. Bogen, O., Bender, O., Löwe, J., Blenau, W., Thevis, B., Schröder, W., Margolis, R. U., Levine, J. D. and Hucho, F. (2015) Neuronally produced versican V2 renders C-fiber nociceptors IB4 -positive. *J Neurochem* **134**, 147-155
7. Hayes, C. E. and Goldstein, I. J. (1974) An alpha-D-galactosyl-binding lectin from Bandeiraea simplicifolia seeds. Isolation by affinity chromatography and characterization. *J Biol Chem* **249**, 1904-1914
8. Bogen, O., Dreger, M., Gillen, C., Schröder, W. and Hucho, F. (2005) Identification of versican as an isolectin B4-binding glycoprotein from mammalian spinal cord tissue. *FEBS J* **272**, 1090-1102
9. Parada, C. A., Yeh, J. J., Reichling, D. B. and Levine, J. D. (2003) Transient attenuation of protein kinase Cepsilon can terminate a chronic hyperalgesic state in the rat. *Neuroscience* **120**, 219-226
10. Ferrari, L. F., Bogen, O. and Levine, J. D. (2010) Nociceptor subpopulations involved in hyperalgesic priming. *Neuroscience* **165**, 896-901
11. Joseph, E. K. and Levine, J. D. (2010) Hyperalgesic priming is restricted to isolectin B4-positive nociceptors. *Neuroscience* **169**, 431-435
12. Bogen, O., Alessandri-Haber, N., Chu, C., Gear, R. W. and Levine, J. D. (2012) Generation of a pain memory in the primary afferent nociceptor triggered by PKCε activation of CPEB. *J Neurosci* **32**, 2018-2026
13. Reichling, D. B. and Levine, J. D. (2009) Critical role of nociceptor plasticity in chronic pain. *Trends Neurosci* **32**, 611-618
14. Kandasamy, R. and Price, T. J. (2015) The pharmacology of nociceptor priming. *Handb Exp Pharmacol* **227**, 15-37
15. Aley, K. O., Messing, R. O., Mochly-Rosen, D. and Levine, J. D. (2000) Chronic hypersensitivity for inflammatory nociceptor sensitization mediated by the epsilon isozyme of protein kinase C. *J Neurosci* **20**, 4680-4685
16. Khasar, S. G., Burkham, J., Dina, O. A., Brown, A. S., Bogen, O., Alessandri-Haber, N., Green, P. G., Reichling, D. B. and Levine, J. D. (2008) Stress induces a switch of intracellular signaling in sensory neurons in a model of generalized pain. *J Neurosci* **28**, 5721-5730
17. Eijkelkamp, N., Wang, H., Garza-Carbajal, A., Willemen, H. L., Zwartkruis, F. J., Wood, J. N., Dantzer, R., Kelley, K. W., Heijnen, C. J. and Kavelaars, A. (2010) Low nociceptor

GRK2 prolongs prostaglandin E2 hyperalgesia via biased cAMP signaling to Epac/Rap1, protein kinase Cepsilon, and MEK/ERK. *J Neurosci* **30**, 12806-12815
18. Wang, H., Heijnen, C. J., van Velthoven, C. T., Willemen, H. L., Ishikawa, Y., Zhang, X., Sood, A. K., Vroon, A., Eijkelkamp, N. and Kavelaars, A. (2013) Balancing GRK2 and EPAC1 levels prevents and relieves chronic pain. *J Clin Invest* **123**, 5023-5034
19. Kitchener, P. D., Wilson, P. and Snow, P. J. (1993) Selective labelling of primary sensory afferent terminals in lamina II of the dorsal horn by injection of Bandeiraea simplicifolia isolectin B4 into peripheral nerves. *Neuroscience* **54**, 545-551
20. Wang, H., Rivero-Melián, C., Robertson, B. and Grant, G. (1994) Transganglionic transport and binding of the isolectin B4 from Griffonia simplicifolia I in rat primary sensory neurons. *Neuroscience* **62**, 539-551
21. Vulchanova, L., Olson, T. H., Stone, L. S., Riedl, M. S., Elde, R. and Honda, C. N. (2001) Cytotoxic targeting of isolectin IB4-binding sensory neurons. *Neuroscience* **108**, 143-155
22. Bogen, O., Dina, O. A., Gear, R. W. and Levine, J. D. (2009) Dependence of monocyte chemoattractant protein 1 induced hyperalgesia on the isolectin B4-binding protein versican. *Neuroscience* **159**, 780-786
23. Ye, Y., Dang, D., Viet, C. T., Dolan, J. C. and Schmidt, B. L. (2012) Analgesia targeting IB4-positive neurons in cancer-induced mechanical hypersensitivity. *J Pain* **13**, 524-531
24. Pinto, L. G., Souza, G. R., Kusuda, R., Lopes, A. H., Sant'Anna, M. B., Cunha, F. Q., Ferreira, S. H. and Cunha, T. M. (2019) Non-Peptidergic Nociceptive Neurons Are Essential for Mechanical Inflammatory Hypersensitivity in Mice. *Mol Neurobiol* **56**, 5715-5728
25. Levine, J. D. and Taiwo, Y. O. (1989) Involvement of the mu-opiate receptor in peripheral analgesia. *Neuroscience* **32**, 571-575
26. Araldi, D., Bogen, O., Green, P. G. and Levine, J. D. (2019) Role of Nociceptor Toll-like Receptor 4 (TLR4) in Opioid-Induced Hyperalgesia and Hyperalgesic Priming. *J Neurosci* **39**, 6414-6424
27. Dorn, G. W., Souroujon, M. C., Liron, T., Chen, C. H., Gray, M. O., Zhou, H. Z., Csukai, M., Wu, G., Lorenz, J. N. and Mochly-Rosen, D. (1999) Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation. *Proc Natl Acad Sci U S A* **96**, 12798-12803
28. Taiwo, Y. O. and Levine, J. D. (1991) Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia. *Neuroscience* **44**, 131-135
29. Papir-Kricheli, D., Frey, J., Laufer, R., Gilon, C., Chorev, M., Selinger, Z. and Devor, M. (1987) Behavioural effects of receptor-specific substance P agonists. *Pain* **31**, 263-276
30. Mestre, C., Pélissier, T., Fialip, J., Wilcox, G. and Eschalier, A. (1994) A method to perform direct transcutaneous intrathecal injection in rats. *J Pharmacol Toxicol Methods* **32**, 197-200
31. Alvarez, P., Bogen, O., Green, P. G. and Levine, J. D. (2017) Nociceptor interleukin 10 receptor 1 is critical for muscle analgesia induced by repeated bouts of eccentric exercise in the rat. *Pain* **158**, 1481-1488
32. Schmittgen, T. D. and Livak, K. J. (2008) Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc* **3**, 1101-1108

33. Kitchener, P. D., Wilson, P. and Snow, P. J. (1993) Selective labelling of primary sensory afferent terminals in lamina II of the dorsal horn by injection of Bandeiraea simplicifolia isolectin B4 into peripheral nerves. *Neuroscience* **54**, 545-551
34. Fang, X., Djouhri, L., McMullan, S., Berry, C., Waxman, S. G., Okuse, K. and Lawson, S. N. (2006) Intense isolectin-B4 binding in rat dorsal root ganglion neurons distinguishes C-fiber nociceptors with broad action potentials and high Nav1.9 expression. *J Neurosci* **26**, 7281-7292
35. Corder, G., Castro, D. C., Bruchas, M. R. and Scherrer, G. (2018) Endogenous and Exogenous Opioids in Pain. *Annu Rev Neurosci* **41**, 453-473
36. Volkow, N., Benveniste, H. and McLellan, A. T. (2018) Use and Misuse of Opioids in Chronic Pain. *Annu Rev Med* **69**, 451-465
37. Kurreck, J. (2004) Antisense and RNA interference approaches to target validation in pain research. *Curr Opin Drug Discov Devel* **7**, 179-187
38. Sarret, P., Doré-Savard, L. and Beaudet, N. (2010) Direct application of siRNA for in vivo pain research. *Methods Mol Biol* **623**, 383-395
39. Kaur, I. P. and Sharma, G. (2012) siRNA: a new approach to target neuropathic pain. *BioDrugs* **26**, 401-412
40. Mohan, A., Fitzsimmons, B., Zhao, H. T., Jiang, Y., Mazur, C., Swayze, E. E. and Kordasiewicz, H. B. (2018) Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain. *Pain* **159**, 139-149
41. Dong, Y., Siegwart, D. J. and Anderson, D. G. (2019) Strategies, design, and chemistry in siRNA delivery systems. *Adv Drug Deliv Rev* **144**, 133-147
42. Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y. and Liang, X. J. (2020) Therapeutic siRNA: state of the art. *Signal Transduct Target Ther* **5**, 101
43. Bennett, C. F., Kordasiewicz, H. B. and Cleveland, D. W. (2021) Antisense Drugs Make Sense for Neurological Diseases. *Annu Rev Pharmacol Toxicol* **61**, 831-852
44. Juliano, R. L. (2016) The delivery of therapeutic oligonucleotides. *Nucleic Acids Res* **44**, 6518-6548
45. Crooke, S. T., Wang, S., Vickers, T. A., Shen, W. and Liang, X. H. (2017) Cellular uptake and trafficking of antisense oligonucleotides. *Nat Biotechnol* **35**, 230-237
46. Xia, X., Pollock, N., Zhou, J. and Rossi, J. (2019) Tissue-Specific Delivery of Oligonucleotides. *Methods Mol Biol* **2036**, 17-50
47. Alshaer, W., Zureigat, H., Al Karaki, A., Al-Kadash, A., Gharaibeh, L., Hatmal, M. M., Aljabali, A. A. A. and Awidi, A. (2021) siRNA: Mechanism of action, challenges, and therapeutic approaches. *Eur J Pharmacol* **905**, 174178
48. Dowdy, S. F. (2017) Overcoming cellular barriers for RNA therapeutics. *Nat Biotechnol* **35**, 222-229
49. Lai, J., Gold, M. S., Kim, C. S., Bian, D., Ossipov, M. H., Hunter, J. C. and Porreca, F. (2002) Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. *Pain* **95**, 143-152
50. Marger, F., Gelot, A., Alloui, A., Matricon, J., Ferrer, J. F., Barrère, C., Pizzoccaro, A., Muller, E., Nargeot, J., Snutch, T. P., Eschalier, A., Bourinet, E. and Ardid, D. (2011) T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. *Proc Natl Acad Sci U S A* **108**, 11268-11273

51. Conner, L. B., Alvarez, P., Bogen, O. and Levine, J. D. (2016) Role of Kv4.3 in Vibration-Induced Muscle Pain in the Rat. *J Pain* **17**, 444-450
52. Luo, X., Fitzsimmons, B., Mohan, A., Zhang, L., Terrando, N., Kordasiewicz, H. and Ji, R. R. (2018) Intrathecal administration of antisense oligonucleotide against p38α but not p38β MAP kinase isoform reduces neuropathic and postoperative pain and TLR4-induced pain in male mice. *Brain Behav Immun* **72**, 34-44
53. Zhang, J., Rong, L., Shao, J., Zhang, Y., Liu, Y., Zhao, S., Li, L., Yu, W., Zhang, M., Ren, X., Zhao, Q., Zhu, C., Luo, H., Zang, W. and Cao, J. (2021) Epigenetic restoration of voltage-gated potassium channel Kv1.2 alleviates nerve injury-induced neuropathic pain. *J Neurochem* **156**, 367-378
54. Zhu, X., Xie, W., Zhang, J., Strong, J. A. and Zhang, J. M. (2022) Sympathectomy decreases pain behaviors and nerve regeneration by downregulating monocyte chemokine CCL2 in dorsal root ganglia in the rat tibial nerve crush model. *Pain* **163**, e106-e120
55. Winkler, J. (2013) Oligonucleotide conjugates for therapeutic applications. *Ther Deliv* **4**, 791-809
56. Chu, T. C., Twu, K. Y., Ellington, A. D. and Levy, M. (2006) Aptamer mediated siRNA delivery. *Nucleic Acids Res* **34**, e73
57. Alam, M. R., Ming, X., Fisher, M., Lackey, J. G., Rajeev, K. G., Manoharan, M. and Juliano, R. L. (2011) Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. *Bioconjug Chem* **22**, 1673-1681
58. Alam, M. R., Ming, X., Nakagawa, O., Jin, J. and Juliano, R. L. (2013) Covalent conjugation of oligonucleotides with cell-targeting ligands. *Bioorg Med Chem* **21**, 6217-6223
59. Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., Riney, S., Booten, S. L., Murray, S. F., Gaus, H., Crosby, J., Lima, W. F., Guo, S., Monia, B. P., Swayze, E. E. and Seth, P. P. (2014) Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. *Nucleic Acids Res* **42**, 8796-8807
60. Ämmälä, C., Drury, W. J., Knerr, L., Ahlstedt, I., Stillemark-Billton, P., Wennberg-Huldt, C., Andersson, E. M., Valeur, E., Jansson-Löfmark, R., Janzén, D., Sundström, L., Meuller, J., Claesson, J., Andersson, P., Johansson, C., Lee, R. G., Prakash, T. P., Seth, P. P., Monia, B. P. and Andersson, S. (2018) Targeted delivery of antisense oligonucleotides to pancreatic β-cells. *Sci Adv* **4**, eaat3386
61. Harumoto, T., Iwai, H., Tanigawa, M., Kubo, T., Atsumi, T., Tsutsumi, K., Takashima, M., Destito, G., Soloff, R., Tomizuka, K., Nycholat, C., Paulson, J. and Uehara, K. (2022) Enhancement of Gene Knockdown on CD22-Expressing Cells by Chemically Modified Glycan Ligand-siRNA Conjugates. *ACS Chem Biol* **17**, 292-298
62. Joseph, E. K., Chen, X., Bogen, O. and Levine, J. D. (2008) Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. *J Pain* **9**, 463-472
63. Wang, R., Guo, W., Ossipov, M. H., Vanderah, T. W., Porreca, F. and Lai, J. (2003) Glial cell line-derived neurotrophic factor normalizes neurochemical changes in injured dorsal root ganglion neurons and prevents the expression of experimental neuropathic pain. *Neuroscience* **121**, 815-824
64. Streit, W. J., Schulte, B. A., Balentine, D. J. and Spicer, S. S. (1985) Histochemical localization of galactose-containing glycoconjugates in sensory neurons and their processes

in the central and peripheral nervous system of the rat. *J Histochem Cytochem* **33**, 1042-1052
65. Fullmer, J. M., Riedl, M., Williams, F. G., Sandrin, M. and Elde, R. (2007) Enzymes that synthesize the IB4 epitope are not sufficient to impart IB4 binding in dorsal root ganglia of rat. *J Comp Neurol* **501**, 70-82
66. Price, T. J. and Flores, C. M. (2007) Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential vanilloid subfamily type 1 immunoreactivities, and isolectin B4 binding in primary afferent neurons of the rat and mouse. *J Pain* **8**, 263-272
67. Weber, P. C., Ohlendorf, D. H., Wendoloski, J. J. and Salemme, F. R. (1989) Structural origins of high-affinity biotin binding to streptavidin. *Science* **243**, 85-88
68. Green, N. M. (1990) Avidin and streptavidin. *Methods Enzymol* **184**, 51-67
69. Walder, R. Y. and Walder, J. A. (1988) Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. *Proc Natl Acad Sci U S A* **85**, 5011-5015
70. Crooke, S. T. (2004) Antisense strategies. *Curr Mol Med* **4**, 465-487
71. Xia, C. F., Boado, R. J. and Pardridge, W. M. (2009) Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. *Mol Pharm* **6**, 747-751
72. Juliano, R. L. (2018) Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don't. *Nucleic Acid Ther* **28**, 166-177
73. Guo, S., Zhang, M. and Huang, Y. (2023) Three 'E' challenges for siRNA drug development. *Trends Mol Med* S1471-4914(23)00240
74. Dowdy, S. F. (2023) Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem. *RNA* **29**, 396-401
75. Summer, G. J., Romero-Sandoval, E. A., Bogen, O., Dina, O. A., Khasar, S. G. and Levine, J. D. (2008) Proinflammatory cytokines mediating burn-injury pain. *Pain* **135**, 98-107
76. Araldi, D., Khomula, E. V., Bonet, I. J. M., Bogen, O., Green, P. G. and Levine, J. D. (2023) Role of pattern recognition receptors in chemotherapy-induced neuropathic pain. *Brain* awad339
77. Al Shaer, D., Al Musaimi, O., Albericio, F. and de la Torre, B. G. (2022) 2021 FDA TIDES (Peptides and Oligonucleotides) Harvest. *Pharmaceuticals (Basel)* **15**, 222
78. de la Torre, B. G. and Albericio, F. (2023) The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules. *Molecules* **28**, 1038